Press Releases
Page 1 of 27
Onxeo has received approval for the delisting from Nasdaq Main Market Copenhagen and the concurrent admission to trading on Nasdaq First North Growth Market Denmark
Last day of trading on Nasdaq Copenhagen will be 11 December 2020 and the first day of trading on Nasdaq […]
11/30/2020
Onxeo Has Applied for Admission to Trading on Nasdaq First North Growth Market Denmark and Delisting from Nasdaq Main Market Copenhagen
Paris (France), November 27, 2020 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
11/27/2020
Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results
The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]
Tags: AsiDNA™
11/09/2020
Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors
This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]
Tags: AsiDNA™
10/22/2020
Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan
Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]
Tags: AsiDNA™
10/21/2020
Publication of the 2020 Half-Yearly Financial Report
Paris (France), September 29, 2020 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
09/29/2020
Onxeo reports its financial results for the first half of 2020 and provides an update on its activities
The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]
09/17/2020
Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020
Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
09/08/2020
Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]
Tags: AsiDNA™
09/03/2020
Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer
DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]
Tags: AsiDNA™
08/27/2020
Page 1 of 27